July 2024

M.Sc Biotechnology, M.Pharm Biotechnology with first class and preferably GPAT qualified. Experience in cell culture, basic molecular biology techniques. project on Development of a low-cost diagnostics kit based on miRNA detection for hepatocellular carcinoma

Masters Degree in any stream of Life Sciences along with NET, GATE and two years of research experience. Masters Degree in Biotechnology, Life Sciences, Biochemistry, Allied biological Sciences discipline; Transition metal-catalyzed fluorine insertion in small organic molecules; Design and Synthesis of Biased Kappa Opioid receptor Agonists for treating Chronic Pain

M.Sc, M.S. in Chemistry from recognized university or equivalent. Research experience in the organic synthesis will be preferred. Active Pharmaceutical Ingredients for Affordable Health Care

Preparation of Freedom to operate opinion for various jurisdictions including USA, Australia, Brazil, China, and EMB markets

M.Pharm / M.Sc; A thorough knowledge related to development, and analytical troubleshooting for Ophthalmic, Injectables and NDDS formulations. In-depth analytical knowledge of techniques and operations viz HPLC, GC, LCMS, PSD, IVRT, Extractable-Leachable.

As a Scientist, Clinical Trial Safety, you will play a pivotal role in reviewing large amounts of clinical data to ensure patient data is complete and medically accurate. support the team during study start-up activities, review patient-level clinical/safety data on an ongoing basis, schedule and facilitate different types of meetings, and create visualizations from applicable tools.

In this role you are required to solve routine problems, largely through precedent and referral to general guidelines. Your primary interaction is within your own team and your direct supervisor 

Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn UKB and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals.

Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva UNIGE, University Hospital of Geneva HUG, and Inserm has made a breakthrough by identifying some of the genetic and energetic characteristics of these stem cells, notably a specific iron utilisation process.